Botulinum toxin use in patients with neurological disorders: A <scp>U.S.</scp> ‐based claims database analysis
Increased understanding of BoNT treatment persistency in clinical practice is essential to help to optimize patient care. This study opens the discussion and field for future studies about why many patients discontinue BoNT therapy after only one or two treatment cycles. Further research will help to determine the underlying reasons for cessation of treatment.
Authors
- Jonathan Bouchard (ORCID: https://orcid.org/0000-0002-8976-1847)
- Sean Page (ORCID: https://orcid.org/0000-0001-6799-6592)
- Seth Goldfarb
- David M. Simpson
- Atul T. Patel
Institutions
- Ipsen (United Kingdom) (GB)
- Ipsen (United States) (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- PM&R
- Published
- 2026-03-11
- DOI
- https://doi.org/10.1002/pmrj.70105
- Primary Topic
- Botulinum Toxin and Related Neurological Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00